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Résumé en
anglais
In patients consulting in the Emergency Department for chest pain, a HEART score ≤
3 has been shown to rule out an acute coronary syndrome (ACS) with a low risk of
major adverse cardiac event (MACE) occurrence. A negative CARE rule (≤ 1) that
stands for the first four elements of the HEART score may have similar rule-out
reliability without troponin assay requirement. We aim to prospectively assess the
performance of the CARE rule and of the HEART score to predict MACE in a chest
pain population. Prospective two-center non-interventional study. Patients admitted
to the ED for non-traumatic chest pain were included, and followed-up at 6 weeks.
The main study endpoint was the 6-week rate of MACE (myocardial infarction,
coronary angioplasty, coronary bypass, and sudden unexplained death). 641 patients
were included, of whom 9.5% presented a MACE at 6 weeks. The CARE rule was
negative for 31.2% of patients, and none presented a MACE during follow-up [0, 95%
confidence interval: (0.0–1.9)]. The HEART score was ≤ 3 for 63.0% of patients, and
none presented a MACE during follow-up [0% (0.0–0.9)]. With an incidence below 2%
in the negative group, the CARE rule seemed able to safely rule out a MACE without
any biological test for one-third of patients with chest pain and the HEART score for
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